Oct 28 (Reuters) - Regis Healthcare Ltd (REG)
- Re-Affirm company's guidance with regard to financial results for 2017 financial year
- FY17 EBITDA is anticipated to be at least 15% in excess of normalised FY16
- With regard to FY17 debt will remain at approximately 2x ebitda, which will result in higher interest expense in FY17, being circa $8m
- Total capex spend in FY17 is anticipated to be in order of $160m
- FY17 depreciation expense range will be $28m - $31m
- "Currently we are tracking in line with our plan and forecast"
- "FY17 debt will remain at approximately 2x ebitda which will result in higher interest expense in FY17, being circa $8m"
Oct 28 (Reuters) - Regis Healthcare Ltd (REG) Re-Affirm...
Add REG (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.48 |
Change
-0.220(3.28%) |
Mkt cap ! $1.755B | |||
| Open | High | Low | Value | Volume |
| $6.75 | $6.87 | $6.48 | $36.64M | 5.637M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $6.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.48 | 8854 | 1 |
View Market Depth
| Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
| REG (ASX) Chart |
